Cingulate (CING)
Develops once-daily ADHD medicines using a multi-core timed-release platform.
Something off on this page? Send us feedback.
Its lead candidate, CTx-1301, uses Precision Timed Release to deliver dexmethylphenidate across the day in a once-daily tablet. The clinical-stage company's FDA application received a Complete Response Letter seeking manufacturing information.
Built around a multi-core delivery platform, Precision Timed Release (PTR) is designed to give CTx-1301 three timed releases of dexmethylphenidate in a once-daily tablet for ADHD. The company remains clinical-stage and conducts operations through its wholly owned subsidiary, Cingulate Therapeutics LLC (CTx). This is the company's lead ADHD program.
CTx-1301 entered FDA review for ADHD after adult and pediatric trials and other FDA-requested studies. The FDA issued a Complete Response Letter requesting specified chemistry, manufacturing, and controls information; Cingulate said the letter did not identify current clinical-safety or efficacy concerns.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 23, 2026 | Roth Capital | Target | Target: $10 | Target: $9 |
| May 19, 2026 | Roth Capital | Target | Target: $11 | Target: $10 |
| Nov 20, 2024 | Maxim Group | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $28.4M · Total debt $6.3M · Total assets $33.1M · Shareholders' equity $23.5M
- Revenue
- $0
- Operating income
- −$5.4M
- Net income
- −$5.9M
No dividends on record.
| Institutions | 12.58% | 1.83M shares | |
|---|---|---|---|
| 38 holders · as of Jun 30, 2026 | |||
| Insiders | 1.78% | 259.3K shares | |
| 7 holders · as of Jun 8, 2026 | |||
| Strategic holders | 26.52% | 3.86M shares | |
| 1 holder · as of Mar 26, 2026 | |||
| Other | 59.12% | 8.60M shares | |
| remainder | |||
14.54M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Falcon Creek Capital Advisor LLCStrategic | 26.52% | 3.86M | filed Mar 26, 2026 |
Vanguard Capital Management LLCInstitution | 3.93% | 570,873 | as of Jun 30, 2026 |
Chicago Partners Investment Group LLCInstitution | 1.30% | 188,429 | as of Jun 30, 2026 |
Raymond James Financial IncInstitution | 1.15% | 166,898 | as of Jun 30, 2026 |
Kestra Advisory Services, LLCInstitution | 1.04% | 151,500 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 13, 2026 | Thomas Jeffrey Hargroves | director | +175,097 | $5.04 |
| Feb 6, 2026 | Matthew Brams | officer: EVP and Chief Medical Officer | +3,502 | $5.04 |
| Feb 6, 2026 | Shane J. Schaffer | director, officer: Chief Executive Officer | +12,256 | $5.04 |
| Feb 6, 2026 | Jennifer L. Callahan | officer: SVP and CFO | +8,755 | $5.04 |
| Feb 6, 2026 | Peter J. Werth | director | +35,019 | $5.04 |
- Novartis (ADR)
Reference-listed dexmethylphenidate XR therapy for ADHD
- Collegium Pharmaceutical
AZSTARYS in once-daily dexmethylphenidate ADHD therapy
- Takeda (ADR)
Vyvanse and Adderall XR in stimulant ADHD treatment
- Supernus Pharmaceuticals
Qelbree in once-daily ADHD treatment across age groups
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cingulate | $5.02 | −2.43% | $69.3M | — | — | — | — |
| Novartis (ADR) | $142.68 | +0.99% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| Collegium Pharmaceutical | $21.84 | −4.13% | $738.8M | 18.4 | 3.2 | 0.9 | +6.3% |
| Takeda (ADR) | $18.82 | −0.69% | $60.30B | 52.9 | 59.8 | 2.0 | +4.2% |
| Supernus Pharmaceuticals | $43.48 | −0.62% | $2.54B | — | 15.0 | 3.1 | +32.4% |
| Median | 21.3 | 15.1 | 2.6 | +5.3% |